.. Bénéfices-thérapeutiques-apportés-par-le-bévacizumab, 77 B.3.1 Cancer Colorectal métastatique (CCRm), p.78

F. +. Le-protocole, AVASTIN associe le bévacizumab avec une chimiothérapie de 2 médicaments anticancéreux (le 5-FU et l'irinotécan commercialisé sous le nom CAMPTO)

. Heures, Ce protocole peut être répété toutes les 2 semaines jusqu'à atteindre le nombre de cycles voulus

H. Abedi and I. Zachary, Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells, Journal of Biological Chemistry, vol.269, issue.24, pp.15442-15451, 1997.
DOI : 10.1083/jcb.135.5.1383

S. Aisenbrey, F. Ziemssen, and M. Völker, Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration, Graefe's Archive for Clinical and Experimental Ophthalmology, vol.25, issue.7, pp.941-949, 2007.
DOI : 10.1001/archopht.117.10.1329

R. Amato, M. Loughnan, and E. Flynn, Thalidomide is an inhibitor of angiogenesis., Proceedings of the National Academy of Sciences, vol.91, issue.9, p.4082, 1994.
DOI : 10.1073/pnas.91.9.4082

T. André and B. Chibaudel, Aflibercept (Zaltrap®) approved in Metastatic Colorectal Cancer. Bull Cancer, pp.1023-1025, 2013.

T. André and S. Dumont, Regorafenib approved in Metastatic Colorectal cancer. Bull Cancer, pp.1027-1029, 2013.

G. Aprile, M. Macerelli, and F. Giuliani, Regorafenib for Gastrointestinal Malignancies, BioDrugs, vol.13, issue.Suppl. 2, p.2013
DOI : 10.1158/1078-0432.CCR-07-0484

S. Bakri, M. Snyder, and J. Pulido, SIX-MONTH STABILITY OF BEVACIZUMAB (AVASTIN) BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER WITHDRAWAL INTO A SYRINGE AND REFRIGERATION OR FREEZING, Retina, vol.26, issue.5, pp.519-541, 2006.
DOI : 10.1097/01.iae.0000225354.92444.7a

J. Beaver and B. Park, The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer, Future Oncology, vol.9, issue.6, pp.651-658
DOI : 10.1093/jnci/djk020

E. Berra, A. Ginouves, and J. Pouyssegur, The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling, EMBO reports, vol.56, issue.1, pp.41-46, 2006.
DOI : 10.1074/jbc.M211058200

URL : https://hal.archives-ouvertes.fr/hal-00321549

A. Bikfalvi, S. Javerzat, C. Perollet, and C. Savona, Angiogenèse et cancer. Bull Cancer, Sept, vol.84, issue.9, pp.885-890, 1997.

N. Ferrara, K. Hillan, W. Novotny, and . Bevacizumab, Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy, Biochemical and Biophysical Research Communications, vol.333, issue.2, pp.328-335, 2005.
DOI : 10.1016/j.bbrc.2005.05.132

N. Ferrara and . Vegf, VEGF and the quest for tumour angiogenesis factors, Nature Reviews Cancer, vol.120, issue.10, pp.795-803, 2002.
DOI : 10.1001/archopht.120.3.338

G. Fong, Mechanisms of adaptive angiogenesis to tissue hypoxia, Angiogenesis, vol.336, issue.1, pp.121-161, 2008.
DOI : 10.4161/cc.6.5.3922

D. Franz, Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex, Biologics: Targets and Therapy, vol.7, pp.211-221, 2013.
DOI : 10.2147/BTT.S25095

R. Frost and C. Lang, mTor Signaling in Skeletal Muscle During Sepsis and Inflammation: Where Does It All Go Wrong?, Physiology, vol.262, issue.2, pp.83-96, 2011.
DOI : 10.1016/j.freeradbiomed.2010.07.006

URL : http://physiologyonline.physiology.org/content/nips/26/2/83.full.pdf

A. Fung, P. Rosenfeld, and E. Reichel, The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide, British Journal of Ophthalmology, vol.90, issue.11, pp.1344-1353, 2006.
DOI : 10.1136/bjo.2006.099598

K. Furugaki, T. Iwai, Y. Moriya, N. Harada, and K. Fujimoto-ouchi, Loss of an EGFRamplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer, 2013.

J. Gera, I. Mellinghoff, and S. Yijiang, Expression, Journal of Biological Chemistry, vol.92, issue.4, pp.2737-2746, 2004.
DOI : 10.1101/gad.1069003

. Inca, La situation du cancer en France en, 2011.

. Inca, Situation de la chimiothérapie des cancers -Rappor t 2012. Collection États des lieux et des connaissances, ouvrage collectif édité par l'INCa, 2013.

A. Janus, T. Robak, and P. Smolewski, The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy, Cell Mol Biol Lett, vol.10, issue.3, pp.479-98, 2005.

F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland et al., Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.23, issue.16, 2005.
DOI : 10.1200/JCO.2005.00.232

F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland et al., Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.23, issue.16, 2005.
DOI : 10.1200/JCO.2005.00.232

R. Kalluri, Angiogenesis: Basement membranes: structure, assembly and role in tumour angiogenesis, Nature Reviews Cancer, vol.3, issue.6, pp.422-455, 2003.
DOI : 10.1038/nrc1094

S. Kapadia, S. Hapani, T. Choueiri, and S. Wu, Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients, Acta Oncologica, vol.28, issue.15, pp.1202-1214, 2013.
DOI : 10.1200/JCO.2011.41.0332

G. Keating and A. Santoro, Sorafenib, Drugs, vol.359, issue.23, pp.223-263, 2009.
DOI : 10.1016/S0076-6879(05)07047-3

S. Keisner and S. Shah, Pazopanib, Drugs, vol.71, issue.4, pp.443-54, 2011.
DOI : 10.2165/11588960-000000000-00000

V. Launay-vacher, O. Bouché, and C. Rioufol, Blocage continu de l'angiogenèse dans le cancer colorectal métastatique : bénéfices et nouvelles stratégies thérapeutiques, J Pharm Clin, vol.31, issue.4, pp.213-236, 2012.

J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.841-844, 1993.
DOI : 10.1038/362841a0

L. Kodjikian, E. Souied, and G. Mimoun, Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial, Ophthalmology, pp.2300-2309, 2013.

V. Kwitkowski, T. Prowell, and I. A. , FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma, The Oncologist, vol.15, issue.4, pp.428-463, 2010.
DOI : 10.1634/theoncologist.2009-0178

URL : http://theoncologist.alphamedpress.org/content/15/4/428.full.pdf

M. Lauzier, Activation de HIF1 dans le cancer : implications et conséquences, Bull Cancer, vol.93, issue.4, 2006.

H. Levine, B. Sleeman, and M. Nilsen-hamilton, A mathematical model for the roles of pericytes and macrophages in the initiation of angiogenesis. I. The role of protease inhibitors in preventing angiogenesis, Mathematical Biosciences, vol.168, issue.1, pp.77-115, 2000.
DOI : 10.1016/S0025-5564(00)00034-1

A. Levy, P. Blanchard, and S. Bellefqih, Strahlentherapie in Kombination mit platinbasierter Chemotherapie oder Cetuximab zur Behandlung von lokal fortgeschrittenen Plattenepithelkarzinomen im Kopf-Hals-Bereich, Strahlentherapie und Onkologie, vol.30, issue.17, 2014.
DOI : 10.1200/JCO.2011.38.4099

A. Lièvre, J. Bachet, L. Corre, and D. , KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.3992, p.66, 2006.

J. Li, M. Perrella, and J. Tsai, Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells, J Biol Chem, 1995.

J. Li, Y. Zhang, and R. Kirsner, Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix, Microscopy Research and Technique, vol.60, issue.1, pp.107-121, 2003.
DOI : 10.1002/jemt.10249

J. Lund, K. Uttervall, and J. Liwing, Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients, European Journal of Haematology, vol.86, issue.1, pp.19-25
DOI : 10.1111/j.1600-0609.2010.01524.x

M. Maemondo, A. Inoue, and K. Kobayashi, Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.2380-2388, 2010.
DOI : 10.1056/NEJMoa0909530

W. Marasco and J. Sui, The growth and potential of human antiviral monoclonal antibody therapeutics, Nature Biotechnology, vol.49, issue.12, pp.1421-1455, 2007.
DOI : 10.1111/j.1348-0421.2005.tb03735.x

N. Maruotti, T. Annese, F. Cantatore, and D. Ribatti, Macrophages and angiogenesis in rheumatic diseases. Vasc Cell, p.11, 2013.

D. Martin, M. Maguire, G. Ying, . Catt-research, and . Group, Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration, Ophthalmology, vol.119, issue.7, 2011.
DOI : 10.1016/j.ophtha.2012.03.053

T. Matsumoto, VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis, The EMBO Journal, vol.277, issue.13, pp.2342-2353, 2005.
DOI : 10.4049/jimmunol.165.6.2927

T. Makinen, T. Veikkola, and S. Mustjoki, Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the, 2001.
DOI : 10.1093/emboj/20.17.4762

URL : http://emboj.embopress.org/content/embojnl/20/17/4762.full.pdf

V. Matuskova, P. Kolaf, and D. Vyslouzilova, Ranibizumab in the ARMD wet form of agerelated macular degeneration treatment -two years results obtained from the AMADEuS Registry, Cesk Slov Oftalmol, vol.68, issue.5, pp.171-178, 2012.

M. Mcmullen, P. Bryant, C. Glembotski, P. Vincent, and K. Pumiglia, Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells, Journal of Biological Chemistry, vol.63, issue.22
DOI : 10.1172/JCI3326

S. Michels, P. Rosenfeld, and C. Puliafito, Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study, Ophthalmology, vol.112, issue.6, pp.1035-1082, 2005.
DOI : 10.1016/j.ophtha.2005.02.007

K. Miller, M. Wang, and J. Gralow, Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer, New England Journal of Medicine, vol.357, issue.26, 2007.
DOI : 10.1056/NEJMoa072113

M. Mita, K. Sankhala, and I. Abdel-karim, Deforolimus (AP23573) a novel mTOR inhibitor in clinical development, Expert Opinion on Investigational Drugs, vol.23, issue.12, pp.1947-54, 2008.
DOI : 10.1016/j.ejca.2006.03.015

T. Mok, Y. Wu, and S. Thongprasert, Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

A. Montero, K. Avancha, S. Glück, and G. Lopes, A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer, Breast Cancer Research and Treatment, vol.45, issue.8, pp.747-51
DOI : 10.1016/j.ejca.2008.12.016

R. Montesano, M. Pepper, and L. Orci, Paracrine induction of angiogenesis in vitro by Swiss 3T3 fibroblasts, Journal of Cell Science, vol.105, pp.1013-1024, 1992.

G. Morgan and F. Davies, Role of thalidomide in the treatment of patients with multiple myeloma, Critical Reviews in Oncology/Hematology, vol.88, issue.1, pp.14-22, 2013.
DOI : 10.1016/j.critrevonc.2013.05.012

R. Motzer, B. Escudier, and S. Oudard, Phase 3 trial of everolimus for metastatic renal cell carcinoma, Cancer, vol.356, issue.suppl, 2010.
DOI : 10.1002/cncr.25219

Y. Muller, B. Li, and W. Hans, Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site, Proc. Natl Acad
DOI : 10.1073/pnas.93.12.5688

Y. Muller, Y. Chen, and H. Christinger, VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 ?? resolution and mutational analysis of the interface, Structure, vol.6, issue.9, pp.1153-67, 1998.
DOI : 10.1016/S0969-2126(98)00116-6

H. Mutlu, A. Büyükçelik, Z. Akça, N. Kaya, J. Nagy et al., unitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis, J Oncol Pharm ract J. Exp, 2002.

S. North, M. Moenner, and A. Bikfalvi, Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors, Cancer Letters, vol.218, issue.1, pp.1-14, 2005.
DOI : 10.1016/j.canlet.2004.08.007

H. Takagi and H. Oh, VEGF receptor signalling in control of vascular function Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes, Nature review Invest Ophthalmol Vis Sci, vol.7, issue.41, pp.1192-1199, 2000.

A. Palumbo, R. Hajek, and M. Delforge, Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1759-69, 2012.
DOI : 10.1056/NEJMoa1112704

URL : https://iris.unito.it/bitstream/2318/120025/1/nejmoa1112704.pdf

E. Paplomata, A. Zelnak, and R. O-'regan, Everolimus: side effect profile and management of toxicities in breast cancer, Breast Cancer Research and Treatment, vol.47, issue.9, 2013.
DOI : 10.1016/j.ejca.2011.02.014

S. Park, M. Chung, and J. Park, Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response, Gut and Liver, vol.7, issue.5, pp.611-616, 2013.
DOI : 10.5009/gnl.2013.7.5.611

T. Perren, A. Swart, J. Pfisterer, and J. Ledermann, A Phase 3 Trial of Bevacizumab in Ovarian Cancer, ICON7 Investigators, pp.2484-96, 2011.
DOI : 10.1056/NEJMoa1103799

J. Pe-'er, D. Shweiki, A. Itin, I. Hemo, H. Gnessin et al., Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases Emerging roles for antiangiogenesis factors in management of ocular disease, Laboratory Investigation; a Journal of Technical Methods and Pathology Clin Ophthalmol, vol.726, issue.130, pp.638-645533, 1995.

D. Salani, D. Castro, V. Nicotra, and M. , Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma, The American Journal of Pathology, vol.157, issue.5, pp.1537-1547, 2000.
DOI : 10.1016/S0002-9440(10)64791-8

A. Sandler, J. Schiller, and R. Gray, Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non???Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab, Journal of Clinical Oncology, vol.27, issue.9, pp.1405-1417, 2009.
DOI : 10.1200/JCO.2008.16.2412

V. Adenoviral, overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes

D. Sarbassov, S. Ali, D. Kim, and D. Guertin, Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton, Current Biology, vol.14, issue.14, pp.1296-1302
DOI : 10.1016/j.cub.2004.06.054

D. Sarbassov, D. Guertin, and S. Ali, Phosphorylation and regulation of, 0135.

. Akt, PKB by the rictor-mTOR complex, Science, vol.307, pp.1098-101, 2005.

A. Scheen, nomenclature internationale des différents types d'anticorps monoclonaux, Rev Med Liège, vol.64, pp.5-6, 2009.

. Schmidt-erfurth, G. Lang, F. Holz, R. Shah, J. Morganroth et al., Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.5, pp.491-503, 2013.
DOI : 10.1016/j.ophtha.2013.11.041

S. Sharma, D. Bell, J. Settleman, and D. Haber, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-81, 2007.
DOI : 10.1016/S1525-7304(11)70394-1

F. Shepherd, Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005.
DOI : 10.1056/NEJMoa050753

D. Shweiki, M. Neeman, A. Itin, and E. Keshet, Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis., Proceedings of the National Academy of Sciences, vol.92, issue.3, pp.92-768, 1995.
DOI : 10.1073/pnas.92.3.768

C. Sibertin-blanc, E. Norguet, and M. Duluc, Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report, BMC Research Notes, vol.6, issue.1, p.471, 2013.
DOI : 10.1016/j.healun.2008.03.016

S. Soefje, A. Karnad, and A. Brenner, Common toxicities of mammalian target of rapamycin inhibitors, Targeted Oncology, vol.118, issue.46, pp.125-134, 2011.
DOI : 10.1016/j.amjmed.2005.02.014

X. Song, Y. Kusakari, and C. Xiao, mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy, American Journal of Physiology-Cell Physiology, vol.269, issue.6, pp.1256-66, 2010.
DOI : 10.1161/01.RES.0000264081.78659.45

G. Stavri, I. Zachary, and P. Baskerville, Basic Fibroblast Growth Factor Upregulates the Expression of Vascular Endothelial Growth Factor in Vascular Smooth Muscle Cells : Synergistic Interaction With Hypoxia, Circulation, vol.92, issue.1, pp.11-14, 1995.
DOI : 10.1161/01.CIR.92.1.11

C. Sternberg, I. Davis, and J. Mardiak, Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6
DOI : 10.1200/JCO.2009.23.9764

J. Tabernero, E. Van-cutsem, and R. Lakomý, Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial, European Journal of Cancer, vol.50, issue.2, pp.959-804900853, 2013.
DOI : 10.1016/j.ejca.2013.09.013

T. Takahashi, S. Yamaguchi, K. Chida, and M. Shibuya, A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells, The EMBO Journal, vol.20, issue.11, pp.2768-78, 2001.
DOI : 10.1093/emboj/20.11.2768

Z. Wang, J. Xu, W. Nie, G. Huang, J. Tang et al., Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis, European Journal of Clinical Pharmacology, vol.20, issue.5, 2013.
DOI : 10.1093/annonc/mdn713

H. Wasan, A. Meade, and A. , Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial, The Lancet Oncology, vol.15, issue.6, pp.1470-204570106, 2014.
DOI : 10.1016/S1470-2045(14)70106-8

R. Wenger, -regulated gene expression, The FASEB Journal, vol.16, issue.10, pp.1151-1162, 2002.
DOI : 10.1073/pnas.95.17.10188

L. Wu and M. Martínez-castellanos, Twelve-month safety of intravitreal injections of bevacizumab (Avastin??): results of the Pan-American Collaborative Retina Study Group (PACORES), Graefe's Archive for Clinical and Experimental Ophthalmology, vol.90, issue.3, pp.81-88, 2008.
DOI : 10.1007/s00417-007-0660-z

F. Xi-bao-yu, M. Zi, and . Yi, Xue Za Zhi. mTOR/p70s6k signaling pathway is involved in megakaryocyte polyploidization, pp.21-25, 2012.

M. Yamaoka-tojo, IQGAP1, a Novel Vascular Endothelial Growth Factor Receptor Binding Protein, Is Involved in Reactive Oxygen Species--Dependent Endothelial Migration and Proliferation, Circulation Research, vol.95, issue.3, pp.276-283, 2004.
DOI : 10.1161/01.RES.0000136522.58649.60

J. Yao, M. Shah, and T. Ito, Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-537, 2011.
DOI : 10.1056/NEJMoa1009290

J. Zambrowski, Coût des thérapies ciblées dans le cancer colorectal métastatique, J Pharm Clin, vol.31, issue.1, pp.5-9, 2012.

C. Zhang, P. Zhao, and X. Li, Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month followup, Chin Med J (Engl), vol.126, issue.15, pp.2826-2835, 2013.